Myeloma: Update on supportive care strategies

被引：0
作者：
Jesús F. San Miguel
Ramón García-Sanz
机构：
[1] Department of Hematology, University Hospital of Salamanca, Paso de San Vicente 52-182, Salamanca
来源：
Current Treatment Options in Oncology | 2003年 / 4卷 / 3期
关键词：
Hypercalcemia; Ibandronate; Multiple Myeloma; Pamidronate; Zoledronic Acid;
D O I：
10.1007/s11864-003-0026-7
中图分类号：
学科分类号：
摘要：
Despite substantial innovations in the treatment of multiple myeloma (MM), it remains an incurable disease. In addition, it is debatable whether the progress in survival is attributable simply to the therapy used to destroy the tumor clone or if it is also because of therapy designed to ameliorate disease complications. Supportive therapy has evolved greatly alongside general supportive measures used in hematologic malignancies (such as new antibiotics, antifungal agents, and growth factors) in addition to better indications in complementary treatments such as radiotherapy, dialysis, and surgery. However, in MM, several specific adjuvant therapies have also been introduced (eg, bisphosphonates and erythroid-stimulating factors), which have conferred a key role to supportive therapy in the general treatment of patients with MM. © 2003, Current Science Inc.
引用
收藏
页码：247 / 258
页数：11
相关论文
共 51 条
[11]  
Ludwig H., Rai K., Blade J., Et al., Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations, Hematol J, 3, pp. 121-130, (2002)
[12]  
Rizzo J.D., Lichtin A.E., Woolf S.H., Et al., Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology, Blood, 100, pp. 2303-2320, (2002)
[13]  
Egrie J.C., Browne J.K., Development and characterization of novel erythropoiesis stimulating protein (NESP), Br J Cancer, 84, pp. 3-10, (2001)
[14]  
Hedenus M., Hansen S., Taylor K., Et al., Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies, Br J Haematol, 119, pp. 79-86, (2002)
[15]  
Cazzola M., Mercuriali F., Brugnara C., Use of recombinant human erythropoietin outside the setting of uremia, Blood, 89, pp. 4248-4267, (1997)
[16]  
Mittelman M., Neumann D., Peled A., Et al., Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models, Proc Natl Acad Sci U S A, 98, pp. 5181-5186, (2001)
[17]  
Hargreaves R.M., Lea J.R., Griffiths H., Et al., Immunological factors and risk of infection in plateau phase myeloma, J Clin Pathol, 48, pp. 260-266, (1995)
[18]  
Fassas A.B., Bolanos-Meade J., Buddharaju L.N., Et al., Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma, Br J Haematol, 112, pp. 1032-1033, (2001)
[19]  
Lortholary O., Ascioglu S., Moreau P., Et al., Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myeloma, Clin Infect Dis, 30, pp. 41-46, (2000)
[20]  
Vallejo C., Caballero M.D., Garcia-Sanz R., Et al., Sequential intravenous-oral ciprofloxacin plus amoxycillin/ clavulanic acid shortens hospital stay in infected non-severe neutropenic patients, Hematol Cell Ther, 39, pp. 223-227, (1997)
123456